Country music singer Toby Keith reveals he has stomach cancer
Toby Keith revealed the news on Sunday, saying he received the diagnosis in the fall. #tobykeith (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2022 Category: Consumer Health News Source Type: news
Toby Keith announces stomach cancer diagnosis from last fall
Toby Keith announced his stomach cancer diagnosis from last fall. #tobykeith (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2022 Category: Consumer Health News Source Type: news
Toby Keith Reveals Stomach Cancer Diagnosis: ‘I Need Time to Breathe, Recover and Relax’
The country music star says he’s spent the last six months receiving treatment for the disease. #countrymusicstar (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2022 Category: Consumer Health News Source Type: news
Country music superstar Toby Keith announces he's been fighting stomach cancer
Country music superstar Toby Keith has announced he has been battling stomach cancer since late last year but has received treatment and plans to return to the stage soon. #tobykeith #countrymusicsuperstar (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2022 Category: Consumer Health News Source Type: news
Country singer Toby Keith diagnosed with stomach cancer
Keith has been in treatment for the past six months following his diagnosis last fall, he announced on Twitter Sunday afternoon. #tobykeith (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2022 Category: Consumer Health News Source Type: news
Does Stomach Cancer Pain Come and Go?
Title: Does Stomach Cancer Pain Come and Go?Category: Diseases and ConditionsCreated: 4/14/2021 12:00:00 AMLast Editorial Review: 6/9/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 9, 2022 Category: Cancer & Oncology Source Type: news
What Are the Symptoms of Stomach Cancer in a Woman?
Title: What Are the Symptoms of Stomach Cancer in a Woman?Category: Diseases and ConditionsCreated: 4/14/2021 12:00:00 AMLast Editorial Review: 6/8/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 8, 2022 Category: Cancer & Oncology Source Type: news
Liver cancer symptoms: The sign in your stomach that could point to the disease
SOME people never experience symptoms of liver cancer. While for others there are telltale signs - although they can be hard to spot. Like all cancers, the quicker the disease is caught, the better chance there is of survival. (Source: Daily Express - Health)
Source: Daily Express - Health - June 7, 2022 Category: Consumer Health News Source Type: news
Cancer warning: The vitamin deficiency doubling your risk of stomach cancer - symptoms
WHEN it comes to boosting your cancer risk, there are the obvious offenders, such as smoking and drinking alcohol. However, an expert shared with Express.co.uk that a certain vitamin deficiency may also play a role. (Source: Daily Express - Health)
Source: Daily Express - Health - June 5, 2022 Category: Consumer Health News Source Type: news
Weight Loss Surgery Is Linked to a Dramatic Drop in Cancer Risk: Study
Obesity is linked to a number of health issues, including Type 2 diabetes, hypertension, heart disease, liver problems, and joint disorders. But many people might not know that the condition is also closely tied to cancer.
In a study published in JAMA, researchers provide the strongest evidence yet supporting the link between obesity and cancer, and the benefits of weight-loss surgery in lowering the risk of developing or dying from cancer.
The trial involved more than 30,000 patients with obesity: some of whom had bariatric surgery for weight loss, and some who served as non-surgical controls and received standard care fo...
Source: TIME: Health - June 3, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthscienceclimate Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
FAPI-PET shows promise detecting biliary tract cancer
Fibroblast-activation protein inhibitor (FAPI)-PET imaging proved to be superio...Read more on AuntMinnie.comRelated Reading:
Dual-tracer PET/CT shows promise in cancer imaging
FAPI-PET may improve diagnosis of gastric cancer
Ga-68 radiotracer outperforms F-18 FDG in lung cancer staging
New tracer bests FDG for diagnosing liver cancer
PET imaging lays foundation for new cancer therapies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 23, 2022 Category: Radiology Source Type: news
H pylori May Undermine Immunotherapy Response in Gastric Cancer H pylori May Undermine Immunotherapy Response in Gastric Cancer
H pylori infection was associated with shorter progression-free and overall survival. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 20, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
